Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study

NCT01617629 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Epithelial Ovarian Cancer

Interventions

BIOLOGICAL: MUC1 Dendritic Cell Vaccine (Cvac)

Sponsor

Prima BioMed Ltd